BAFNA PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.36 INR | +5.00% |
|
+15.75% | -5.04% |
| Sales 2022 | 851M 10.2M | Sales 2023 | 1.15B 13.82M | Capitalization | 1.94B 23.24M |
|---|---|---|---|---|---|
| Net income 2022 | 51M 611K | Net income 2023 | 113M 1.35M | EV / Sales 2022 | 3.65 x |
| Net Debt 2022 | 109M 1.3M | Net Debt 2023 | 151M 1.81M | EV / Sales 2023 | 1.81 x |
| P/E ratio 2022 |
58.4
x | P/E ratio 2023 |
17.1
x | Employees | 588 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 10.36% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.00% | ||
| 1 week | +15.75% | ||
| Current month | +15.75% | ||
| 1 month | +2.24% | ||
| 3 months | -1.23% | ||
| 6 months | -10.49% | ||
| Current year | -5.04% |
1 week
79.24
87.36
1 month
73.2587.36
Current year
73.25113.00
1 year
73.25119.00
3 years
73.25185.50
5 years
4.40233.55
10 years
4.40233.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 80-12-31 | |
M. Sridhar
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 80-12-31 | |
Krishna Yeachuri
BRD | Director/Board Member | 63 | 23-06-25 |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 87.36 | +5.00% | 957 |
| 24-07-02 | 83.2 | +5.00% | 3,692 |
| 24-07-01 | 79.24 | +5.00% | 4,933 |
End-of-day quote NSE India S.E., July 02, 2024
More quotes
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Companyâs subsidiary is Bafna Lifestyles Remedies Limited.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.04% | 24.75M | |
| +23.51% | 44.09B | |
| +30.04% | 23.18B | |
| +21.21% | 15.66B | |
| +18.62% | 14.35B | |
| +62.42% | 13.2B | |
| -0.05% | 6.79B | |
| -11.78% | 6.45B | |
| -8.87% | 5.73B | |
| +14.11% | 5.63B |
- Stock Market
- Equities
- BAFNAPH Stock
